<?xml version='1.0' encoding='utf-8'?>
<document id="26195223"><sentence text="Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8."><entity charOffset="54-66" id="DDI-PubMed.26195223.s1.e0" text="pioglitazone" /><entity charOffset="71-82" id="DDI-PubMed.26195223.s1.e1" text="gemfibrozil" /><entity charOffset="84-112" id="DDI-PubMed.26195223.s1.e2" text="Gemfibrozil acyl-glucuronide" /><pair ddi="false" e1="DDI-PubMed.26195223.s1.e0" e2="DDI-PubMed.26195223.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26195223.s1.e0" e2="DDI-PubMed.26195223.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26195223.s1.e0" e2="DDI-PubMed.26195223.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s1.e1" e2="DDI-PubMed.26195223.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26195223.s1.e1" e2="DDI-PubMed.26195223.s1.e2" /></sentence><sentence text="While co-administered gemfibrozil can increase the area under the concentration/time curve (AUC) of pioglitazone more than 3-fold, the underlying mechanism of the drug-drug interaction between gemfibrozil and pioglitazone has not been fully understood"><entity charOffset="22-33" id="DDI-PubMed.26195223.s2.e0" text="gemfibrozil" /><entity charOffset="100-112" id="DDI-PubMed.26195223.s2.e1" text="pioglitazone" /><entity charOffset="193-204" id="DDI-PubMed.26195223.s2.e2" text="gemfibrozil" /><entity charOffset="209-221" id="DDI-PubMed.26195223.s2.e3" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e0" e2="DDI-PubMed.26195223.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e0" e2="DDI-PubMed.26195223.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e0" e2="DDI-PubMed.26195223.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e0" e2="DDI-PubMed.26195223.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e1" e2="DDI-PubMed.26195223.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e1" e2="DDI-PubMed.26195223.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e1" e2="DDI-PubMed.26195223.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e2" e2="DDI-PubMed.26195223.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s2.e2" e2="DDI-PubMed.26195223.s2.e3" /></sentence><sentence text=" In the present study, gemfibrozil preincubation time-dependently inhibited the metabolism of pioglitazone in the cytochrome P450 (CYP)- and UDP-glucuronosyltransferase (UGT)-activated human liver microsomes"><entity charOffset="23-34" id="DDI-PubMed.26195223.s3.e0" text="gemfibrozil" /><entity charOffset="94-106" id="DDI-PubMed.26195223.s3.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26195223.s3.e0" e2="DDI-PubMed.26195223.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26195223.s3.e0" e2="DDI-PubMed.26195223.s3.e1" /></sentence><sentence text=" We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0"><entity charOffset="135-146" id="DDI-PubMed.26195223.s4.e0" text="gemfibrozil" /></sentence><sentence text="071 min(-1) and 57" /><sentence text="3 μM, respectively" /><sentence text=" In this study, the kobs, in vivo value was defined as a parameter that indicates the potency of the mechanism-based inhibitory effect at the blood drug concentration in vivo" /><sentence text=" The kobs, in vivo values of potent mechanism-based inhibitors, clarithromycin and erythromycin, were estimated to be 0"><entity charOffset="64-78" id="DDI-PubMed.26195223.s8.e0" text="clarithromycin" /><entity charOffset="83-95" id="DDI-PubMed.26195223.s8.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.26195223.s8.e0" e2="DDI-PubMed.26195223.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26195223.s8.e0" e2="DDI-PubMed.26195223.s8.e1" /></sentence><sentence text="0096 min(-1) and 0" /><sentence text="0051 min(-1), respectively" /><sentence text=" The kobs, in vivo value of gemfibrozil was 0"><entity charOffset="28-39" id="DDI-PubMed.26195223.s11.e0" text="gemfibrozil" /></sentence><sentence text="0060 min(-1), which was comparable to those of clarithromycin and erythromycin, suggesting that gemfibrozil could be a mechanism-based inhibitor as potent as clarithromycin and erythromycin in vivo"><entity charOffset="47-61" id="DDI-PubMed.26195223.s12.e0" text="clarithromycin" /><entity charOffset="66-78" id="DDI-PubMed.26195223.s12.e1" text="erythromycin" /><entity charOffset="96-107" id="DDI-PubMed.26195223.s12.e2" text="gemfibrozil" /><entity charOffset="158-172" id="DDI-PubMed.26195223.s12.e3" text="clarithromycin" /><entity charOffset="177-189" id="DDI-PubMed.26195223.s12.e4" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e0" e2="DDI-PubMed.26195223.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e0" e2="DDI-PubMed.26195223.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e0" e2="DDI-PubMed.26195223.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e0" e2="DDI-PubMed.26195223.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e0" e2="DDI-PubMed.26195223.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e1" e2="DDI-PubMed.26195223.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e1" e2="DDI-PubMed.26195223.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e1" e2="DDI-PubMed.26195223.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e1" e2="DDI-PubMed.26195223.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e2" e2="DDI-PubMed.26195223.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e2" e2="DDI-PubMed.26195223.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e2" e2="DDI-PubMed.26195223.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e3" e2="DDI-PubMed.26195223.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26195223.s12.e3" e2="DDI-PubMed.26195223.s12.e4" /></sentence><sentence text=" " /></document>